Association between cerebrospinal fluid protein level and peripheral nerve demyelination in patients with Guillain-Barré syndrome
10.3969/j.issn.1674-8115.2017.10.012
- VernacularTitle:吉兰-巴雷综合征患者脑脊液蛋白水平与周围神经髓鞘损伤的相关性分析
- Author:
Min WANG
1
;
hua Zhao ZHOU
;
biao Shi DENG
;
yu Jie ZHANG
;
Ting YU
;
sheng De ZHU
;
yan Yun HE
Author Information
1. 南昌大学 抚州医学院病原教研室
- Keywords:
neural immune;
Guillain-Barré syndrome;
peripheral nerve;
cerebrospinal fluid protein;
demyelination
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2017;37(10):1372-1375
- CountryChina
- Language:Chinese
-
Abstract:
Objective · To explore the association between cerebrospinal fluid (CSF) protein level and peripheral nerve demyelination in patients with Guillain-Barré syndrome (GBS). Methods · Clinical and biochemical data of 86 patients with GBS were retrospectively analyzed. According to electromyograms examination of peripheral nerve, GBS patients were divided into group with demyelination and group with axonal degeneration, and their clinical and biochemical characteristics were compared between the two groups. The correlation between CSF protein level and peripheral nerve demyelination was assessed by Spearman's correlation analysis. Results · Between the group with demyelination and group with axonal degeneration,there was no significant difference in gender, age, Hughes score, respiratory infection, gastrointestinal infection, erythra, ganglioside sodium injection and immunoglobulin G (IgG) index (P>0.05). Significant higher level of CSF protein, CSF albumin/serum albumin, IgG, and 24 h IgG intrathecal synthesis rate were detected in group with demyelination than that of in group with axonal degeneration (P<0.01). CSF protein level was positively correlated with peripheral nerve demyelination (r=0.345, P=0.001). Conclusion · The incidence of peripheral nerve demyelination increased accompanied with CSF protein level, and analysis of CSF protein level may be helpful in investigating the immunologic mechanism of peripheral nerve demyelination in GBS patients.
